is that we know that this drug can cause deaths. When the drug came out and got FDA approval they said that the Stevens-Johnson reaction was reversible in the patients who had it. We now know that is not the case.
Now HCV is a chronic disease, and you are taking the drugs to prevent death many years from now.
But you have a certain probability of dying on this therapy.
Very difficult to advise your patient to take this when other alternatives- non-deadly- are available or on the horizon
Incivek was always doomed; the strategy as they have stated is to wring as much revenue as they can out of Incivek while understanding that all oral therapies are the future. Incivek has no strategic importance for the company. This will, however, affect revenues to some degree in 2013. Hastening European funding of Kalydeco could reverse the effect on revenue.